This page shows the latest Chimerix news and features for those working in and with pharma, biotech and healthcare.
The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of pivotal trials.
Patients in the brincidofovir arm also showed an increase in mortality compared to the control arm, but the increase was not statistically significant, according to Chimerix. ... Both GVHD and use of corticosteroids are risk factors for 'late' CMV
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Anti-infective deals. A similar size to the Genmab deal at $168m is the agreement between Chimerix, a US based private company developing antiviral therapies and Merck &Co. ... 178. Chimerix / Merck &Co. Licence. Lipid antiviral conjugate in phase 1 for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Chimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman. ... Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
No results were found
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...